Scientific Article
previous document  unige:9471  next document
add to browser collection

Immunomodulateurs en rhumatologie et risques infectieux

Published in Revue médicale suisse. 2006, vol. 2, no. 57, p. 738-740, 743-735
Abstract Corticosteroids and cytotoxic drugs form the conventional immunomodulators in rheumatology. This therapeutic arsenal has recently been widened by TNF-alpha antagonists and other anti-cytokines. If rheumatoid arthritis is itself associated with infections, immunomodulating therapies further increase the risk of infection, especially when used in combination therapies. Among conventional therapies, corticosteroids are associated with the highest risk for both common bacterial and opportunistic infections. Infliximab is the TNF-alpha antagonist associated with the highest risk of infection. Its use has been particularly associated with cases of severe tuberculosis. All patients at risk for tuberculosis, treated with corticosteroids or TNF-alpha antagonists, should therefore receive an adequate prophylaxis.
Keywords Adrenal Cortex Hormones/administration & dosage/ adverse effectsArthritis, Rheumatoid/ drug therapyBacterial Infections/ etiologyHumansImmunosuppressive Agents/administration & dosage/ adverse effectsOpportunistic Infections/ etiologyRiskTumor Necrosis Factor-alpha/antagonists & inhibitors
PMID: 16604876
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
(ISO format)
VAN DELDEN, Christian. Immunomodulateurs en rhumatologie et risques infectieux. In: Revue médicale suisse, 2006, vol. 2, n° 57, p. 738-740, 743-735.

150 hits

0 download


Deposited on : 2010-07-12

Export document
Format :
Citation style :